Eloxx Pharmaceuticals Stock Performance
| ELOX Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Eloxx Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Eloxx Pharmaceuticals are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile basic indicators, Eloxx Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Eloxx |
Eloxx Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.00 in Eloxx Pharmaceuticals on October 10, 2025 and sell it today you would earn a total of 0.01 from holding Eloxx Pharmaceuticals or generate 9.223372036854776E16% return on investment over 90 days. Eloxx Pharmaceuticals is currently generating 15.873% in daily expected returns and assumes 125.9882% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Eloxx, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Eloxx Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eloxx Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Eloxx Pharmaceuticals, and traders can use it to determine the average amount a Eloxx Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.126
| Best Portfolio | Best Equity | ELOX | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Eloxx Pharmaceuticals is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eloxx Pharmaceuticals by adding it to a well-diversified portfolio.
Eloxx Pharmaceuticals Fundamentals Growth
Eloxx Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Eloxx Pharmaceuticals, and Eloxx Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eloxx Pink Sheet performance.
| Return On Equity | -6.15 | |||
| Return On Asset | -0.73 | |||
| Current Valuation | 30.28 M | |||
| Shares Outstanding | 2.75 M | |||
| Price To Earning | (7.94) X | |||
| Price To Book | 6.31 X | |||
| EBITDA | (34.42 M) | |||
| Cash And Equivalents | 30.05 M | |||
| Cash Per Share | 0.35 X | |||
| Total Debt | 13.38 M | |||
| Book Value Per Share | (7.46) X | |||
| Cash Flow From Operations | (31.84 M) | |||
| Earnings Per Share | (12.93) X | |||
| Total Asset | 21.12 M | |||
| Retained Earnings | (274.39 M) | |||
| Current Asset | 3.84 M | |||
| Current Liabilities | 840.05 K | |||
About Eloxx Pharmaceuticals Performance
Evaluating Eloxx Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Eloxx Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Eloxx Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts. Eloxx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.Things to note about Eloxx Pharmaceuticals performance evaluation
Checking the ongoing alerts about Eloxx Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Eloxx Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eloxx Pharmaceuticals is way too risky over 90 days horizon | |
| Eloxx Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Eloxx Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Eloxx Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (36.06 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eloxx Pharmaceuticals currently holds about 30.05 M in cash with (31.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Eloxx Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eloxx Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Eloxx Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eloxx Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eloxx Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eloxx Pharmaceuticals' pink sheet. These opinions can provide insight into Eloxx Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Eloxx Pink Sheet Analysis
When running Eloxx Pharmaceuticals' price analysis, check to measure Eloxx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eloxx Pharmaceuticals is operating at the current time. Most of Eloxx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eloxx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eloxx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eloxx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.